ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Continuing a string of acquisitions, Cambrex has agreed to acquire Avista Pharma Solutions for $252 million. Avista is owned by Ampersand Capital Partners and operates three facilities in the U.S. and one in Scotland. It engages in a range of pharmaceutical services, including early-stage small-molecule development and testing as well as finished-dosage services. The deal follows Cambrex’s acquisition of Halo Pharma earlier this year, which added final-dosage services to Cambrex’s offerings.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter